
No products in the cart.

Cancer patients in Pakistan are being sold fake Keytruda vials for a few thousand rupees. A genuine vial of this drug costs between Rs 200,000 and Rs 550,000 and must travel through a licensed, refrigerated supply chain to reach a patient safely. What patients are receiving from grey markets and Instagram sellers contains no active ingredient at all.
This guide covers how counterfeit Keytruda enters Pakistan, what doctors are witnessing in clinics, and exactly what patients and families can do to verify every vial before an infusion begins. In this piece, we’ve discussed key points, including:
Keytruda is the brand name for pembrolizumab, a cancer immunotherapy developed by Merck and approved by the U.S. Food and Drug Administration. It works by blocking the PD-1 receptor on cancer cells, which allows the patient’s immune system to recognise and attack tumours. It is one of the most widely used cancer drugs in the world.
Keytruda is used to treat a broad range of cancers, including:
A single box of eight 50mg pembrolizumab vials costs approximately $17,000 in the United States. In Pakistan, one genuine 100mg injection costs between Rs 200,000 and Rs 550,000. That enormous price tag makes Keytruda one of the most counterfeited oncology drugs in the world.
Senior oncologists across Pakistan are regularly seeing patients who bring in Keytruda vials purchased from grey markets for a few thousand rupees. A Karachi oncologist told The News Pakistan in 2025 that the vials had cloudy solutions, visible floating particles, and less liquid than a real dose should contain. These are clear signs of a falsified medicine that was never manufactured in a licensed facility.
Patients who received these counterfeit vials showed no clinical benefit. Their cancers kept growing while they believed they were receiving treatment. By the time doctors detected the failure, months of irreplaceable treatment time had already been lost.
The physical warning signs of a fake Keytruda vial include:
| Feature | Genuine Keytruda | Counterfeit Warning Signs |
|---|---|---|
| Price in Pakistan | Rs 200,000 to Rs 550,000 per 100mg vial | Sold for a few thousand rupees |
| Solution appearance | Clear, colourless to slightly yellow | Cloudy, discoloured, or contains visible particles |
| Vial fill volume | 4ml for a 100mg dose | Visibly less than standard volume |
| Source | DRAP registered importer or authorised distributor | Grey market, Instagram, or informal contact |
| Packaging | Merck holographic label, printed batch and expiry | Inconsistent label quality, missing DRAP number |
| Clinical outcome | Measurable immune response and tumour reduction | No benefit, cancer continues to advance |
DRAP has already finalised pembrolizumab pricing and endorsed it at multiple regulatory levels. Pharmaceutical companies cannot legally import and market Keytruda in Pakistan because the federal cabinet has not yet issued a formal notification to complete the process. That single administrative step is the only thing blocking the entire authorised supply chain.
While the paperwork sits unactioned, black market operators have completely filled the gap. Pakistan Chemists and Druggists Association chairman Abdul Samad Budhani told The News that pharmacies are approached daily by patients seeking medicines not registered for legal sale in the country. The Pakistan Medical Association has called this situation a humanitarian crisis and urged the government to expedite approvals and act against those running the illegal drug trade.
Currently, patients are switching to alternative pembroluzimab products like:
Quality Assured100% Authentic

Pembroxim 100mg/4ml (Pembrolizumab)
Pembroxim 100mg/4ml (Pembrolizumab) is a receptor-1 (PD 1)-blocking antibody for advanced cancers.…₨ 180,000
Quality Assured100% Authentic

Pemomab (Ziska Pharma)
Buy Pemomab (Pembroluzimab) a crtical cancer medication online at PakMeds. We offer…₨ 180,000
Quality Assured100% Authentic

Brolizum (Pembrolizumab) 100mg
Buy Brolizum online with a valid prescription at PakMeds. We deliver authentic…₨ 180,000
Fake Keytruda enters Pakistan through two main routes. The first is local: unregistered factories in unmarked industrial units produce counterfeit injectables in packaging designed to look exactly like Merck’s product. According to a 2025 PLoS One study on counterfeit drugs in Pakistan, more than 100,000 companies manufacture and sell drugs in Pakistan with no registration and no regulatory oversight whatsoever.
The second route is international. Smuggling networks move falsified pembrolizumab through transit hubs like Dubai to hide the country of manufacture before shipments reach Pakistani markets. Once inside the country, corrupt wholesalers distribute these products into pharmacies, clinics, and hospital procurement chains.
Key entry points for fake cancer drugs into Pakistan include:
Fake Keytruda is now advertised openly on Instagram and Facebook. Sellers create pages offering pembrolizumab at dramatically reduced prices, targeting patients and families searching online for a drug they cannot find at any licensed pharmacy. According to GeneOnline’s 2025 investigation, counterfeiters specifically target oncology medications through social media because of the broad reach and easy access to vulnerable patients.
The U.S. Food and Drug Administration issued a formal consumer warning in January 2026 about social media platforms including Instagram being used to sell fake cancer treatments. The FDA’s guidance states that any seller who does not require a valid prescription for a prescription medicine should be treated as suspicious. Pakistani patients should apply that standard to every seller they encounter online.
Red flags to watch for on social media drug sellers include:
In March 2026, the U.S. Department of Justice sentenced Sanjay Kumar, a 45 year old Indian national, to 43 months in federal prison for selling counterfeit Keytruda to cancer patients through online marketplaces. During court proceedings Kumar admitted the substance in his fake vials would do nothing to treat cancer and described it as just like water. As reported by IBTimes UK, federal prosecutors called the conspiracy a direct assault on the hope of vulnerable patients.
In an earlier case documented by Medscape, two Ukrainian nationals pleaded guilty to smuggling fake pembrolizumab into the United States. They sold two boxes of counterfeit 50mg Keytruda, worth over $30,000 at legitimate pharmacy prices, to undercover agents for just $3,400. Laboratory testing confirmed those vials contained no active anticancer ingredients whatsoever.
In January 2025, DRAP exposed a large scale operation distributing fake medicines under international brand names, including products falsely labelled with pharmaceutical company addresses in France and Germany. As ProPakistani reported, DRAP issued a formal recall alert and directed the Punjab government to enhance surveillance and remove the counterfeit drugs through its full regulatory field force.
In November 2024, DRAP directed all provincial governments to crack down on unauthorised medicines after illegal imported drugs were discovered being administered inside Pakistani hospitals. Healthcare advocates have called for capital punishment for those proven guilty of producing and distributing fake cancer medicines, citing direct and fatal consequences for patients.
Key actions DRAP has taken against counterfeit cancer drugs include:
Pakistan’s long border with Afghanistan is a primary entry route for smuggled pharmaceutical products including cancer medicines. Drugs crossing through this route carry no registration, no quality testing, and no documented manufacturing origin. Keytruda must be stored at 2 to 8 degrees Celsius throughout its entire supply chain, and a vial transported across hundreds of kilometres without refrigeration has almost certainly been rendered ineffective before it arrives.
Patients who import pembrolizumab from neighbouring countries to bypass the cabinet notification delay face multiple compounding risks. The drug may be a deliberate counterfeit, an expired batch with relabelled packaging, or a genuine drug destroyed by improper storage during transport. Healthcare experts in Pakistan are clear that restoring the authorised supply chain is the only sustainable solution to this problem.
Every patient receiving Keytruda in Pakistan should complete these verification steps before every new batch of medication is opened. A few minutes of checking can prevent months of ineffective treatment and further cancer progression. Share these steps with your oncologist, your pharmacist, and every family member involved in sourcing the medicine.
Steps to verify a Keytruda vial before infusion:
Roswell Park Comprehensive Cancer Center’s 2025 patient advisory confirms that Keytruda is among the most frequently counterfeited intravenous cancer therapies globally. Their clinical advice is direct: when a patient’s cancer shows no response to Keytruda treatment, one of the first questions should be whether the medicine came from a verified and authorised source.
The federal cabinet must issue the formal notification for pembrolizumab pricing that DRAP has already approved. That one step unlocks legal importation and restores the authorised supply chain. The regulatory work is complete. No new legislation is required and no new agency is needed.
Beyond that, Pakistan needs structural changes to protect cancer patients long term. As former Pakistan Pharmaceutical Manufacturers Association chairman Kaiser Waheed told Dawn, decisions that should take days currently take up to two years to clear the ministry. Cancer patients cannot wait two years.
The structural reforms Pakistan’s drug control system urgently needs include:
Keytruda treats melanoma, non-small cell lung cancer, head and neck cancer, bladder cancer, breast cancer, Hodgkin lymphoma, gastric cancer, cervical cancer, and other solid tumours. It is given as an intravenous infusion every two to three weeks. For many of these cancers, pembrolizumab is the most effective systemic therapy currently available.
Genuine Keytruda 100mg costs between Rs 200,000 and Rs 550,000 per vial in Pakistan depending on the supplier and current exchange rate. Any offer significantly below this range should be treated as a serious warning sign and verified through DRAP before purchase or administration.
DRAP has approved pembrolizumab pricing and endorsed it at multiple regulatory levels, but the federal cabinet has not yet issued the formal notification required for companies to legally import and market the drug. Until that notification is published, authorised commercial importation remains blocked and patients are left without a formal supply chain.
Genuine Keytruda contains a completely clear, colourless to slightly yellow solution with no visible particles, held in a 4ml vial. Cloudy liquid, floating particles, or a visibly underfilled vial are immediate warning signs. Verify the DRAP registration number on the official DRAP website and cross check the batch number with Merck Pakistan before any infusion takes place.
Fake Keytruda contains no pembrolizumab, meaning the patient receives zero immunotherapy benefit while their cancer continues to grow. By the time clinical failure is detected, the disease has typically progressed to a more advanced and harder to treat stage. Some counterfeit vials also contain unknown substances that cause direct physical harm beyond the treatment failure itself.
DRAP conducted raids across Punjab in late 2024 and January 2025 that uncovered counterfeit drug operations using fake European pharmaceutical branding. Recall orders were issued, provincial governments were directed to intensify surveillance, and the regulatory field force was instructed to remove identified fake medicines from circulation. Healthcare experts and the Pakistan Medical Association have urged DRAP to be granted full independence and greater resources for ongoing surveillance rather than reactive periodic raids.
A single unissued federal cabinet notification has blocked legal access to pembrolizumab in Pakistan. It has handed criminal networks the opportunity to fill that gap with fake vials sold through grey markets, Afghan border smuggling routes, and Instagram sellers.
Cancer patients who received these counterfeits lost months of treatment time while their diseases advanced. The regulatory approval is done. The human cost of not acting on it is documented and growing every week.
Verify every Keytruda vial before infusion. Confirm batch numbers with Merck Pakistan without delay. Every cancer patient in Pakistan deserves access to real medicine, and every safeguard available right now is worth taking.
Use this feature to chat with our agent.
Leave a comment